It is difficult to get a man to understand something, when his salary depends upon his not understanding it! – Upton Sinclair
Just one other quick post on this cholesterol issue. Guidelines for adults were last set in 2004 and detailed here. The journal Circulation, failed to print a financial disclosure detailing possible conflict of interest for the authors when these guidelines were first published, a fact I learned by reading Ignore the Awkward.: How the Cholesterol Myths Are Kept Alive
Here is the statement from the Circulation website:
In the article “Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,” by Grundy et al, which appeared in the July 13, 2004 issue of the journal (Circulation. 2004;110:227-239), the link to the financial disclosure of the authors was omitted. The following URL www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm will take readers to the NHLBI’s website for the update, and a link to the disclosure is available from there.
Being the helpful soul that I am, I’ve decided to reprint that missing disclosure for my readers here:
Dr. Grundy has received honoraria from Merck, Pfizer, Sankyo, Bayer, Merck/Schering-Plough, Kos, Abbott, Bristol-Myers Squibb, and AstraZeneca; he has received research grants from Merck, Abbott, and Glaxo Smith Kline.
Dr. Cleeman has no financial relationships to disclose.
Dr. Bairey Merz has received lecture honoraria from Pfizer, Merck, and Kos; she has served as a consultant for Pfizer, Bayer, and EHC (Merck); she has received unrestricted institutional grants for Continuing Medical Education from Pfizer, Procter & Gamble, Novartis, Wyeth, AstraZeneca, and Bristol-Myers Squibb Medical Imaging; she has received a research grant from Merck; she has stock in Boston Scientific, IVAX, Eli Lilly, Medtronic, Johnson & Johnson, SCIPIE Insurance, ATS Medical, and Biosite.
Dr. Brewer has received honoraria from AstraZeneca, Pfizer, Lipid Sciences, Merck, Merck/Schering-Plough, Fournier, Tularik, Esperion, and Novartis; he has served as a consultant for AstraZeneca, Pfizer, Lipid Sciences, Merck, Merck/Schering-Plough, Fournier, Tularik, Sankyo, and Novartis.
Dr. Clark has received honoraria for educational presentations from Abbott, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer; he has received grant/research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer.
Dr. Hunninghake has received honoraria for consulting and speakers bureau from AstraZeneca, Merck, Merck/Schering-Plough, and Pfizer, and for consulting from Kos; he has received research grants from AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Merck/Schering-Plough, Novartis, and Pfizer.
Dr. Pasternak has served as a speaker for Pfizer, Merck, Merck/Schering-Plough, Takeda, Kos, BMS-Sanofi, and Novartis; he has served as a consultant for Merck, Merck/Schering-Plough, Sanofi, Pfizer Health Solutions, Johnson & Johnson-Merck, and AstraZeneca.
Dr. Smith has received institutional research support from Merck; he has stock in Medtronic and Johnson & Johnson.
Dr. Stone has received honoraria for educational lectures from Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Merck/Schering-Plough, Novartis, Pfizer, Reliant, and Sankyo; he has served as a consultant for Abbott, Merck, Merck/Schering-Plough, Pfizer, and Reliant.
And this from the American Heart Association:
The American Heart Association regrets that this information was not made available at the time of initial publication on July 13, 2004″
Yes, regrets all around. Honest mistake no doubt.
For more on this issue, I suggest reading this: Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All Into Patients